絞り込み

16645

広告

HbA1c for Diabetes Screening in Acute Coronary Syndrome: time for a reappraisal of the guidelines?

著者 McCune C , Maynard S , McClements B , Lindsay JR
Ulster Med J.2015 Oct ; 84(3):154-6.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)
Diabetes is highly prevalent in individuals with acute coronary syndrome (ACS). Current NICE guidelines recommend diabetes screening of hyperglycaemic patients using a fasting plasma glucose after 4 days from admission. In 2012 the World Health Organisation (WHO) approved the use of HbA1c in the diagnosis and targeted screening for type 2 diabetes. We introduced a service improvement project using HbA1c for diabetes screening in patients with no previous diagnosis of diabetes admitted with ACS regardless of glycaemic state.
PMID: 26668415 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード